13F reference period
Q2 2026
Security Snapshot
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) Institutional Ownership
CUSIP: 23284F105
13F Institutional Holders and Ownership History from Q4 2015 to Q3 2026
Institutions Reporting
178
Shares (Excl. Options)
213.04M
Full value: 213,036,700 · shares · 30 Jun 2026Price
$3.75
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value per share
- Symbol
- CTMX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 213,036,700
- Total 13F value
- $798,992,521
- Portfolio coverage rank
- 0%
- Share change
- +20,497,088
- Value change
- +$65,019,587
- Number of holders
- 178
- Shares outstanding
- 216,973,139
- SEC-reported price per share
- $2.72
- Insider filing price
- $2.72
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share is tracked under CUSIP 23284F105.
- 178 institutions reported positions in Q2 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 179 to 178 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$907.86M
Full value: $907,862,078 · USD · 31 Mar 2026.$798.99M
Full value: $798,992,521 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 178 institutions filings for Q2 2026.
Security key
23284F105
13F reference period
Q2 2026
13F holders
178
13D/G owners
12
CIK / CUSIP context first
Open Q2 2026 holders
CTMX full holder history
CytomX Therapeutics, Inc. SEC filings
CytomX Therapeutics, Inc. company facts
CytomX Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23284F105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
12
Security
CTMX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +18% | $105,171,344 | +$17,756,285 | 24,688,109 | +20% | FMR LLC | 31 Dec 2025 |
| BlackRock, Inc. | 7.6% | $62,067,945 | 16,551,452 | BlackRock, Inc. | 30 Jun 2026 | |||
| Longitude Capital Partners V, LLC | 7% | -4.3% | $65,740,382 | +$16,125,000 | 15,288,461 | +33% | Patrick G. Enright | 31 Mar 2026 |
| BANK OF AMERICA CORP /DE/ | 7% | $55,998,349 | 15,134,689 | BANK OF AMERICA CORP /DE/ | 30 Jun 2026 | |||
| STATE STREET CORP | 5.4% | $43,464,773 | 11,747,236 | STATE STREET CORPORATION | 30 Jun 2026 | |||
| PERCEPTIVE ADVISORS LLC | 4.6% | -22% | $43,424,943 | +$1,800,148 | 10,098,824 | +4.3% | Perceptive Advisors LLC | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 4.6% | -53% | $42,923,133 | -$23,991,317 | 9,982,124 | -36% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 |
| Point72 Asset Management, L.P. | 3.6% | -28% | $28,900,822 | -$11,298,128 | 7,811,033 | -28% | Point72 Asset Management, L.P. | 30 Jun 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 3.5% | -47% | $17,250,001 | -$17,250,001 | 5,769,231 | -50% | BVF PARTNERS L P/IL | 03 Jul 2025 |
| ORBIMED ADVISORS LLC | 2.1% | -66% | $15,160,295 | -$21,224,155 | 3,525,650 | -58% | OrbiMed Advisors LLC | 31 Dec 2025 |
| Seven Fleet Capital Management LP | 0.5% | $4,667,211 | +$4,456,950 | 1,085,398 | +2120% | Seven Fleet Master Fund LP | 31 Mar 2026 | |
| Seven Fleet Partners LP | 0.2% | $267,784 | 377,161 | Seven Fleet Partners LP | 13 May 2025 |
As of 30 Jun 2026,
178
institutional investors reported holding
shares of
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX).
This represents
98%
of the company’s total
outstanding shares.
213.04M
Full value: 213,036,700 · shares · 30 Jun 2026216.97M
Full value: 216,973,139 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
86%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 32,714,937 | +2.4% | 0.01% | $122,681,014 |
| Kynam Capital Management, LP | 10% | 21,703,093 | +45% | 4.5% | $81,386,599 |
| BlackRock, Inc. | 8.1% | 17,559,822 | +236% | 0% | $65,849,333 |
| BANK OF AMERICA CORP /DE/ | 7% | 15,082,617 | +48% | 0% | $56,559,813 |
| STATE STREET CORP | 5.4% | 11,747,236 | +107% | 0% | $44,052,135 |
| PERCEPTIVE ADVISORS LLC | 4.8% | 10,439,185 | +3.4% | 0.61% | $39,146,944 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 8,525,457 | -2.4% | 0% | $31,970,464 |
| Point72 Asset Management, L.P. | 3.6% | 7,811,033 | -0.82% | 0.04% | $29,291,374 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.4% | 5,168,961 | +44% | 0% | $19,383,605 |
| Venrock Adviser, LLC | 2.3% | 4,982,124 | -50% | 0.57% | $18,682,965 |
| BAKER BROS. ADVISORS LP | 2.3% | 4,975,826 | 0% | 0.09% | $18,659,348 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 4,678,716 | +126% | 0% | $17,548,248 |
| Elmind Capital, LP | 2.1% | 4,550,000 | 0% | 4.3% | $17,062,500 |
| Nextech Invest Ltd. | 2.1% | 4,449,932 | 0% | 0.8% | $16,687,245 |
| TWO SIGMA INVESTMENTS, LP | 1.9% | 4,132,643 | +52% | 0.01% | $15,497,411 |
| Eversept Partners, LP | 1.6% | 3,558,497 | +12% | 0.73% | $13,344,364 |
| UBS Group AG | 1.6% | 3,468,359 | +11% | 0% | $13,006,346 |
| Siren, L.L.C. | 1.6% | 3,457,711 | 0% | 0.26% | $12,966,416 |
| ADAR1 Capital Management, LLC | 1.6% | 3,365,118 | -1.3% | 0.6% | $12,619,193 |
| CITADEL ADVISORS LLC | 1.4% | 3,110,509 | -42% | 0.01% | $11,664,409 |
| MARSHALL WACE, LLP | 1.4% | 3,024,351 | -27% | 0.01% | $11,341,320 |
| Woodline Partners LP | 0.94% | 2,040,210 | +2% | 0.02% | $7,650,788 |
| GOLDMAN SACHS GROUP INC | 0.92% | 2,003,652 | +37% | 0% | $7,513,696 |
| DIMENSIONAL FUND ADVISORS LP | 0.86% | 1,860,290 | -3.7% | 0% | $6,976,220 |
| Qube Research & Technologies Ltd | 0.84% | 1,824,564 | -19% | 0.01% | $6,842,115 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
44
Headline period
Q2 2026
Rows shown
1-25 of 44
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 2,045,198 | $5,562,937 | +$2,814,367 | $2.72 | 17 |
| 2026 Q2 | 213,036,700 | $798,992,521 | +$65,019,587 | $3.75 | 178 |
| 2026 Q1 | 193,169,653 | $907,862,078 | +$226,598,991 | $4.70 | 179 |
| 2025 Q4 | 144,051,943 | $613,664,738 | +$47,313,431 | $4.26 | 122 |
| 2025 Q3 | 137,411,371 | $438,342,190 | +$24,527,196 | $3.19 | 102 |
| 2025 Q2 | 133,305,109 | $302,602,132 | +$213,797,054 | $2.27 | 82 |
| 2025 Q1 | 45,180,958 | $28,723,084 | -$1,507,772 | $0.64 | 63 |
| 2024 Q4 | 46,714,805 | $48,111,898 | -$6,381,441 | $1.03 | 68 |
| 2024 Q3 | 51,193,741 | $60,427,306 | +$480,690 | $1.18 | 69 |
| 2024 Q2 | 50,687,257 | $61,863,474 | +$334,609 | $1.22 | 73 |
| 2024 Q1 | 44,548,308 | $97,118,414 | +$26,024,246 | $2.18 | 85 |
| 2023 Q4 | 32,640,376 | $50,592,909 | +$410,206 | $1.55 | 66 |
| 2023 Q3 | 32,393,313 | $41,785,804 | -$2,418,556 | $1.29 | 61 |
| 2023 Q2 | 34,120,916 | $58,688,106 | -$2,378,087 | $1.72 | 66 |
| 2023 Q1 | 35,594,054 | $53,751,153 | -$933,381 | $1.51 | 74 |
| 2022 Q4 | 35,979,014 | $120,192,376 | -$724,794 | $1.60 | 77 |
| 2022 Q3 | 36,281,610 | $52,604,898 | -$18,986,577 | $1.45 | 76 |
| 2022 Q2 | 45,579,430 | $83,410,352 | -$17,825,825 | $1.83 | 86 |
| 2022 Q1 | 53,661,262 | $143,355,949 | -$1,754,233 | $2.67 | 112 |
| 2021 Q4 | 54,342,875 | $235,299,521 | -$5,313,006 | $4.33 | 106 |
| 2021 Q3 | 53,978,233 | $274,775,521 | -$17,338,127 | $5.09 | 111 |
| 2021 Q2 | 56,688,576 | $358,879,555 | +$4,313,452 | $6.33 | 119 |
| 2021 Q1 | 54,613,642 | $422,156,729 | +$130,257,296 | $7.73 | 123 |
| 2020 Q4 | 37,995,365 | $248,881,255 | +$5,576,359 | $6.55 | 123 |
| 2020 Q3 | 36,841,081 | $245,069,950 | -$11,639,890 | $6.65 | 128 |